Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 65

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 65
---
’s registered office and principal executive offices are located at The Circle6, 8058 Zurich, Switzerland. NLS’s telephone number in Switzerland is +41.44.512.2150 and its website address is https://nlspharma.com. The information contained on, or that can be accessed through, NLS’s website is not part of this proxy statement/prospectus. The website address has been included in this proxy statement/prospectus solely as an inactive textual reference. After the consummation of the Merger, NLS’s principal executive office will remain at The Circle6, 8058 Zurich, Switzerland, Tel: +41.44.512.2150. Merger Sub Merger Sub was incorporated on November 3, 2024 under the laws of the State of Israel, as a wholly -ownedsubsidiary of NLS for the purpose of effecting the Merger and to serve as the vehicle for, and to be subsumed by, Kadimastem pursuant to the Merger. 1 Kadimastem Kadimastem is a clinical -stagepharmaceutical company focused on developing and manufacturing “off -the-shelf” allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells, or hESCs, into functional cells. Kadimastem is primarily developing two products: 1.AstroRx ®, Kadimastem’s lead product, which is an off -the-shelfcryopreserved cell therapy product in clinical development for the treatment for ALS and in pre -clinicalstudies for other neurodegenerative indications. AstroRx ®is comprised of fully differentiated astrocytes, which are mainly cells that support the CNS. 2.IsletRx is Kadimastem’s treatment for diabetes is currently in preclinical development. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with Type 1 diabetes and possibly Type 2 insulin dependent diabetes. The IsletRx development program includes three programs in various preclinical development stages; iTOL -102(Pre -IND), Encap -IsletRx(INTERACT) and In -Scaffold-IsletRx(early development). Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for